co-medication

co-medication

Psychiatry The use of a second medication to alleviate the side effects of another medication
Mentioned in ?
References in periodicals archive ?
Aim: To investigate the effects of CLNAZ co-medication, patient gender, age and CLZ dosage on serum concentration of CLZ and norclozapine (N-CLZ) in individuals with schizophrenia.
Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or equivalent during the entire study (mandatory co-medication for MTX treatment).
For patients between ages 20 and 60, the effect of co-medication was considered weak.
Based on these findings, Malik recommended that patients with a longer history of alcohol abuse or dependence undergo dual-energy X-ray absorptiometry, a measurement of BMD, especially when other risk factors such as co-medication or smoking are present.
Treatment and medication should be tailored to an individual's seizure type, co-medication, lifestyle, and preferences.
The cover picture of Volume 18 addresses the possibility of a co-medication of bioactive natural products with chemotherapeutics or antibiotics.
The shortcomings of most of these reports include difficulties regarding the assessment of co-medication with drugs and dietary supplements (DDS) and inaccuracies regarding the treatment duration, dose, natural course of the liver function tests and exclusion of unrelated diseases.
Further comments have been submitted on Valerian root within the 3-month consultation period, relating to the HMPC' recommendation to avoid co-medication with other sedatives.
Based on current clinical and experimental data, co-medication with SWE should be avoided in patients who are taking anticoagulants of the coumarin type (e.
Furthermore, in many cases, detailed information on the patients' history, co-medication, consumption of alcohol and further particulars were missing, thus not permitting a sound evaluation of these cases.
The rationale for the lack of reference to co-medications is that the agency wants to evaluate the potential for any new chemical entity to alter the pharmacokinetics of endogenous uremic toxins.